#polycythemia vera

20 Oct 2026

Merck KGaA to Acquire Silence Therapeutics for $1.3B

Merck KGaA has agreed to buy British biotech Silence Therapeutics, adding the Phase‑3‑ready siRNA drug divesiran for polycythemia vera to its rare‑disease portfolio.

Read more